Fundraising FoxRegenacy Pharmaceuticals
Waltham, US · Founded 2016 · Delaware corporation · 4 known investors
Find your way into Regenacy Pharmaceuticals
Sign up to see every warm intro you have to Regenacy Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Regenacy Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
SJ
Simon JonesPresident and Chief Executive Officer
MC
JR
John RochaChief Financial Officer
ML
Michael L. HuangNamed on SEC filing
WC
William ChinNamed on SEC filing
SY
Shixiang YanNamed on SEC filing
DW
Daguang WangNamed on SEC filing
Investors · 4
3E Bioventures CapitalreportedPalo Alto
How we know: a partner's Signal profile · markets.financialcontent.com · Not right? Tell us
Cobro VenturesreportedMclean
How we know: funding news · markets.financialcontent.com · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$28.7M disclosed across 2 rounds · 2020–2022
▶$7.8MraisedFeb 2022 · 9 investors · PharmaceuticalsRule 506(b)
▶$7.8MraisedFeb 2022 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Daguang WangDirector
- William ChinDirector
- Simon JonesExecutive Officer, Director
- Shixiang YanDirector
- Michael L. HuangDirector
- Marc CohenExecutive Officer, Director
- John RochaExecutive Officer
- Offering amount
- $10M
- Amount sold
- $7.8M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20.9MraisedApr 2020 · 19 investors · PharmaceuticalsRule 506(b)
▶$20.9MraisedApr 2020 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael L. HuangDirector
- Simon JonesExecutive Officer, Director
- William ChinDirector
- Shixiang YanDirector
- Daguang WangDirector
- Marc CohenExecutive Officer, Director
- John RochaExecutive Officer
- Offering amount
- $40.7M
- Amount sold
- $20.9M
- Sales commissions
- $757.5K
- Placement agents
- Locust Walk Partners, LLC
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Regenacy Pharmaceuticals's investors?
- Regenacy Pharmaceuticals's investors include 3E Bioventures Capital, Cobro Ventures, Taiwania Capital, Yonjin Venture LLC.
- How much funding has Regenacy Pharmaceuticals raised?
- Regenacy Pharmaceuticals has disclosed $28.7M raised across 2 rounds.
- Where is Regenacy Pharmaceuticals headquartered?
- Regenacy Pharmaceuticals is headquartered in Waltham, US.